These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23847384)

  • 21. Impact of the human papilloma vaccine on cervical cancer.
    Chan JK; Berek JS
    J Clin Oncol; 2007 Jul; 25(20):2975-82. PubMed ID: 17617529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses].
    Westra TA; Daemen T; Postma MJ; Wilschut JC
    Ned Tijdschr Geneeskd; 2009; 153():A356. PubMed ID: 19930733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human papillomavirus vaccines to prevent cervical cancer.
    Markman M
    Lancet; 2007 Jun; 369(9576):1837-1839. PubMed ID: 17544748
    [No Abstract]   [Full Text] [Related]  

  • 24. Harnessing the power of prevention: human papillomavirus vaccines.
    Mayeaux EJ
    Curr Opin Obstet Gynecol; 2006 Feb; 18 Suppl 1():s15-21. PubMed ID: 16520680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.
    Poljak M
    Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():64-9. PubMed ID: 22862799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HPV vaccines: state of the art.
    D'Andrilli G; Bovicelli A; Giordano A
    J Cell Physiol; 2010 Sep; 224(3):601-4. PubMed ID: 20432468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Human papillomavirus and carcinoma of the cervix vaccines against the human papillomavirus-promise of an efficacious prevention].
    Kohl I
    Klin Mikrobiol Infekc Lek; 2006 Jun; 12(3):91-7. PubMed ID: 17051469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Latin America. Price is the main barrier to wider use of papillomavirus vaccine.
    Kaiser J
    Science; 2008 May; 320(5878):860. PubMed ID: 18487164
    [No Abstract]   [Full Text] [Related]  

  • 29. Cost-effectiveness of human papilloma virus vaccination in Iceland.
    Oddsson K; Johannsson J; Asgeirsdottir TL; Gudnason T
    Acta Obstet Gynecol Scand; 2009; 88(12):1411-6. PubMed ID: 19900074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human papillomavirus, cervical cancer, and the vaccines.
    Tovar JM; Bazaldua OV; Vargas L; Reile E
    Postgrad Med; 2008 Jul; 120(2):79-84. PubMed ID: 18654072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Implementation of human papillomavirus immunization in the developing world.
    Kane MA; Serrano B; de Sanjosé S; Wittet S
    Vaccine; 2012 Nov; 30 Suppl 5():F192-200. PubMed ID: 23199963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comment on "New paradigm for prevention of cervical cancer" [Eur J Obstet Gynecol Reprod Biol 2007;130(1):25-9].
    Mahajan NN; Gaikwad NL; Soni RN; Mahajan KN
    Eur J Obstet Gynecol Reprod Biol; 2007 Nov; 135(1):140-1; author reply 141. PubMed ID: 17524549
    [No Abstract]   [Full Text] [Related]  

  • 33. New advances in vaccine technology and improved cervical cancer prevention.
    Huh WK; Kendrick JE; Alvarez RD
    Obstet Gynecol; 2007 May; 109(5):1187-92. PubMed ID: 17470604
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strengthening prevention programs to eliminate cervical cancer in the Nordic countries.
    Dillner L; Pagliusi S; Bray F; Lorincz A; Kjaer SK; Anttila A; Iversen OE; Dillner J; Lehtinen M; Paavonen J
    Acta Obstet Gynecol Scand; 2008; 87(5):489-98. PubMed ID: 18446530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HPV vaccines: the beginning of the end for cervical cancer.
    Leggatt GR; Frazer IH
    Curr Opin Immunol; 2007 Apr; 19(2):232-8. PubMed ID: 17293100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
    Bégué P; Henrion R; Blanc B; Girard M; Sancho-Garnier H
    Bull Acad Natl Med; 2007 Dec; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cervical cancer prevention in the human papilloma virus vaccine era.
    Ghazal-Aswad S
    Ann N Y Acad Sci; 2008 Sep; 1138():253-6. PubMed ID: 18837904
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human Pappilomavirus (HPV) induced cancers and prevention by immunization.
    Khaliq SA; Shyum Naqvi SB; Fatima A
    Pak J Pharm Sci; 2012 Oct; 25(4):763-72. PubMed ID: 23009992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications.
    Goldie SJ; O'Shea M; Diaz M; Kim SY
    Reprod Health Matters; 2008 Nov; 16(32):86-96. PubMed ID: 19027626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening.
    Arbyn M; Dillner J
    J Clin Virol; 2007 Mar; 38(3):189-97. PubMed ID: 17258503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.